Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.
Seattle Genetics’ net income was $50.02 million in the third quarter of 2017. It incurred a net loss of $67.45 million in the third quarter of 2018, which translated into a net loss per share of $0.42 in the third quarter of 2018. Seattle Genetics’ net earnings per share were $0.34 in the third quarter of 2017.
In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating, four analysts have given it a “hold” rating, and one analyst has given Seattle Genetics a “sell” rating. The mean rating for Seattle Genetics stock is 2.23 with a target price of $80.36, implying an upside potential of 32.5% over Seattle Genetics’ closing price of $60.65 on December 10, 2018.
In comparison, for peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY), analysts have a mean rating of 2.33, 2.21 and 2.44, respectively, and a target price of $204.8, $86.15, and $114.06, respectively.
Seattle Genetics’ current ratio, a measure of how effectively a company can meet its short-term obligations, stands at 3.70. In comparison, the current ratios of its peers, Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) stand at 3.10, 3.50, and 1.90, respectively.